Pharmacy

Risk for CVD increased in association with glucocorticoid dose, even with <5.0 mg daily prednisolone-equivalent dose

58 percent of adults aged 50 to 80 years report being somewhat or very likely to get a COVID-19 vaccine

Remdesivir, hydroxychloroquine, lopinavir, interferon regimens have little to no effect on in-hospital mortality

No reduction seen in risks for hospital admission, intensive care unit admission, or death due to COVID

Guidance focuses on tailored treatment interventions for specific age groups based on disease severity

Number of foot exams increased, but no improvements seen in other important care continuum measures

Redfield says that the coming winter months are going to be 'the most difficult time in the public health history of this nation'

Pembrolizumab superior to chemo for progression-free survival among patients who had not previously received treatment

Findings seen in preclinical studies of mice, survival data from patients receiving PD-(L)1 blockade for GBM